Jacob Lalezari, MD
CytoDyn, Inc.
7
3
3
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (7)
Research Network
Collaboration Network
Research Areas & Affiliations
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Mike Royal, MD
Sorrento Therapeutics, Inc.
Shared therapeutic areas:
emilie garrido pradalie
APHM
Shared therapeutic areas:
Xiaolong Qi, MD
LanZhou University
Shared therapeutic areas:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Toshimitsu Tokimoto
Astrazeneca KK
Shared therapeutic areas:
Mohamed mamdouh Elsayed, MD
Lecturer
Shared therapeutic areas:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Melissa Stockwell, MD MPH
Columbia University
Shared therapeutic areas:
Jamie Ostroff, PhD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Grace E Parraga, PhD
Robarts Research Institute, The University of Western Ontario
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (7)
Showing 7 of 7 trials
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study
Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study
An Extension of Protocol PRO 140_CD01 Study
All 7 trials loaded